Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer

Drug Discovery Today

Volumn 19, Issue 10, 2014, Pages 1671-1676

  Alama, Angela ^a   Truini, Anna ^a   Coco, Simona ^a   Genova, Carlo ^a   Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CYTOKERATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GEMCITABINE; MAGNETIC NANOPARTICLE; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CELL DIFFERENTIATION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); METASTASIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84908654309     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.001     Document Type: Review

References (53)

1. Fehm, T. et al. (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res. 8, 2073-2084
2. Allard, W.J. et al. (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin. Cancer Res. 10, 6897-6904
3. Ashworth, T.R. (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 14, 146-149
4. Thomson, S. et al. (2011) A systems view of epithelial-mesenchymal transition signaling states. Clin. Exp. Metastasis 28, 137-155
5. Pain, M. et al. (2014) Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur. Respir. Rev. 23, 118-130
6. Lamouille, S. et al. (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell. Biol. 15, 178-196
7. Cristofanilli, M. et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791
8. Cristofanilli, M. et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23, 1420-1430
9. Cohen, S.J. et al. (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6, 125-132
10. Okegawa, T. et al. (2009) Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J. Urol. 18, 1091-1097
11. Hou, J.M. et al. (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am. J. Pathol. 178, 989-996
12. O'Flaherty, J.D. et al. (2012) Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 76, 19-25
13. Siegel, R. et al. (2013) Cancer statistics, 2013. CA Cancer J Clin. 63, 11-30
14. Grossi, F. et al. (2010) Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 15, 1102-1112
15. Genova, C. et al. (2013) Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin. Pharmacother. 14, 1545-1558
16. Aita, M. et al. (2008) Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 68, 183-196
17. Rosell, R. et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13, 239-246
18. Favoni, R.E. and Alama, A. (2013) Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. Drug Discov. Today 18, 11-24
19. Shaw, A.T. et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394
20. Katz, R.L. et al. (2010) Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Cancer Res. 16, 3976-3987
21. Campos, M. et al. (2013) Simultaneous phenotypic and genetic characterization of single circulating tumor cells from colon cancer patients. Histol. Histopathol. 28, 1439-1450
22. Arya, S.K. et al. (2013) Enrichment, detection and clinical significance of circulating tumor cells. Lab Chip 13, 1995-2007
23. Parkinson, D.R. et al. (2012) Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 10, 138
24. Harouaka, R. et al. (2014) Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol. Ther. 141, 209-221
25. Mostert, B. et al. (2011) Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 127, 33-41
26. Oka, S. et al. (2012) The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung. Anticancer Res. 32, 861-864
27. Imbert, A.M. et al. (2012) CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in epithelial to mesenchymal transition. PLoS One 7, e43752
28. Botteri, E. et al. (2010) Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res. Treat. 122, 211-217
29. Garrigos, N. et al. (2010) Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin. Transl. Oncol. 12, 142-147
30. Cohen, S.J. et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213-3221
31. de Bono, J.S. et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309
32. Farace, F. et al. (2011) A direct comparison of CellSearch® and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer 105, 847-853
33. Krebs, M.G. et al. (2012) Analysis of circulating tumor cells in patients with nonsmall cell lung cancer using epithelial marker dependent and -independent approaches. J. Thorac. Oncol. 7, 306-315
34. Chinen, L.T. et al. (2013) Cytokeratin-based CTC counting unrelated to clinical follow up. J. Thorac. Dis. 5, 593-599
35. Fusi, A. et al. (2013) Clinical utility of circulating tumour cell detection in non-small-cell lung cancer. Curr. Treat. Options Oncol. 14, 610-622
36. Sawabata, N. et al. (2007) Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen. Thorac. Cardiovasc. Surg. 55, 189-192
37. Tanaka, F. et al. (2009) Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin. Cancer Res. 15, 6980-6986
38. Hofman, V. et al. (2012) Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 23, 30-38
39. Hofman, V. et al. (2011) Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin. Cancer Res. 17, 827-835
40. Hofman, V. et al. (2011) Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int. J. Cancer 129, 1651-1660
41. Krebs, M.G. et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29, 1557-1563
42. Ma, X.L. et al. (2012) Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac. J. Cancer Prev. 13, 1137-1144
43. Huang, J. et al. (2013) Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS One 8, e78070
44. Maheswaran, S. et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377
45. Punnoose, E.A. et al. (2010) Molecular biomarker analyses using circulating tumor cells. PLoS One 5, e12517
46. Punnoose, E.A. et al. (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a Phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391-2401
47. Ran, R. et al. (2013) Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood. Anal. Bioanal. Chem. 405, 7377-7382
48. Pailler, E. et al. (2013) Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J. Clin. Oncol. doi: 10.1200/JCO.2012.44.5932
49. Heitzer, E. et al. (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 73, 2965-2975
50. Daniels, M. et al. (2012) Whole genome sequencing for lung cancer. J. Thorac. Dis. 4, 155-163
51. Hirose, T. et al. (2012) Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncology Res. 20, 131-137
52. Juan, O. et al. (2013) Prognostic significance of circulating tumor cells in advanced nonsmall cell lung cancer patients treated with docetaxel and gemcitabine. Clin. Transl. Oncol. [Epub ahead of print]
53. Muinelo-Romay, L. et al. (2014) Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment. Cancers 6, 153-165